Document is current
Any future updates will be listed below
-
Authors
Masui, Sho
Yonezawa, Atsushi https://orcid.org/0000-0002-8057-6768
Yokoyama, Kotoko
Iwamoto, Noriko
Shimada, Takashi
Onishi, Akira
Onizawa, Hideo
Fujii, Takayuki
Murakami, Kosaku
Murata, Koichi
Tanaka, Masao
Nakagawa, Shunsaku
Hira, Daiki
Itohara, Kotaro
Imai, Satoshi
Nakagawa, Takayuki
Hayakari, Makoto
Matsuda, Shuichi
Morinobu, Akio
Terada, Tomohiro
Matsubara, Kazuo
-
Funding
Funding for this research was provided by:
KAKENHI (19H03389)
Agencia Nacional de Promoción de la Investigación, el Desarrollo Tecnológico y la Innovación (21mk0101152h0503)
Nakatomi Foundation
- License Information
-
More Information
Article History
Received: 18 May 2022
Accepted: 14 August 2022
First Online: 19 August 2022
Declarations
:
: The Department of Advanced Medicine for Rheumatic Diseases is supported by two local governments (Nagahama City, Shiga, and Toyooka City, Hyogo, Japan) and five pharmaceutical companies (Mitsubishi Tanabe Pharma Co.; Chugai Pharmaceutical Co. Ltd.; UCB Japan Co. Ltd.; Asahi Kasei Pharma Corp.; and AYUMI Pharmaceutical Co.). The KURAMA cohort study is supported by a grant from Daiichi Sankyo Co. Ltd. A.Y. has received a research grant from Shimadzu Corporation and AYUMI Pharmaceutical Co. A.O. reports grants from Pfizer Inc., Bristol-Myers Squibb., Advantest, personal fees from Asahi Kasei Pharma Corp., Chugai Pharmaceutical Co. Ltd., Eli Lilly Japan K.K, Ono Pharmaceutical Co., Mitsubishi Tanabe Pharma Co., Eisai Co. Ltd., Abbvie Inc., Takeda Pharmaceutical Co. Ltd., and Daiichi Sankyo Co. Ltd. T.F. received speaking fees from Eisai Co. Ltd., Asahi Kasei Pharma Corp., Abbvie Inc., and Janssen Pharmaceutical K.K. K.Murata received a speaking fee and/or consulting fees from Eisai Co. Ltd., Chugai Pharmaceutical Co. Ltd.; Asahi Kasei Pharma Corp., Bristol-Myers Squibb, Mitsubishi Tanabe Pharma Co., Janssen Pharmaceutical K.K. and Daiichi Sankyo Co. Ltd. M.T. has received research grants and/or speaker fees from Abbvie Inc., Asahi Kasei Pharma Corp., Astellas Pharma Inc., Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., Eli Lilly Japan K.K., Janssen Pharmaceutical K.K., Kyowa Kirin Co. Ltd., Pfizer Inc., Taisho Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Co., Teijin Pharma, Ltd., UCB Japan Co. Ltd. S. Matsuda received speaker fees from Pfizer Inc. A.M. has received honorarium from AbbVie G.K., Chugai Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., Eisai Co. Ltd., Pfizer Inc., Bristol-Myers Squibb., Mitsubishi Tanabe Pharma Co., Astellas Pharma Inc., and Gilead Sciences Japan., and has received research grants from AbbVie G.K., Asahi Kasei Pharma Corp., Chugai Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Co. and Eisai Co. Ltd.
: Written informed consent to participate in this study was obtained from all patients.
: Not applicable.
: Written informed consent to participate in this cohort study was obtained from all patients. All patients’ data were de-identified and analyzed anonymously. The present study adhered to the principles of the Declaration of Helsinki and was approved by the Medical Ethics Committee of Kyoto University Graduate School and Faculty of Medicine (R0357). All animal studies were conducted in accordance with the guidelines for animal experiments at Kyoto University. The protocols were approved by the Animal Research Committee of the Graduate School of Medicine, Kyoto University (Permission No. MedKyo21113).
